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Introduction:  This article  reports  the  latest  recommendations  of  the French  Society  for  Rheumatology
(SFR)  regarding  the management  of  rheumatoid  arthritis  (RA).
Methods: New  recommendations  were  developed  by  hospital-  and  community-based  rheumatologists
having  extensive  experience  with  RA  and  a patient  self-help  organization  representative.  They  rest  on
the  recently  issued  EULAR  recommendations  and  a literature  review.
Results: Points  emphasized  in  the  15  recommendations  include  the  need  to  share  treatment  decisions
between  the  rheumatologist  and  the  patient,  the  acquisition  by  patients  of self-management  skills,  remis-
sion  or  minimal  disease  activity  as  the  treatment  target,  the  need  for initiating  disease-modifying  drugs
as  early  as  possible,  and  the  usefulness  of  regular  disease  activity  assessments  to  allow  rapid  treatment
adjustments  if needed  (i.e.,  tight  disease  control).  First-line  methotrexate  monotherapy  is  recommended,
with  concomitant  short-term  glucocorticoid  therapy  if indicated  by the  risk/beneﬁt  ratio.  Patients  who
fail  this  approach  (no  response  after  3 months  or target  not  achieved  after  6 months)  can  be  considered  for
another  synthetic  disease-modifying  antirheumatic  drug  (DMARD:  leﬂunomide  or sulfasalazine),  com-
bined  synthetic  DMARD  therapy,  or methotrexate  plus  a biologic,  depending  on  the  prognostic  factors
and  patient  characteristics.  If the ﬁrst  biologic  fails,  switching  to a second  biologic  is  recommended.  In the
event  of a sustained  remission,  cautious  dosage  reduction  of the biological  and/after  synthetic  DMARDs
is  in order.
Conclusion:  These  recommendations  are  designed  to  improve  the  management  of patients  with  RA.
de rh© 2014 Société franc¸ aise 
. Introduction
CC BY-NC-ND license.Rheumatoid arthritis (RA) is the most common inﬂammatory
oint disease in adults, with an estimated prevalence of 0.3% to
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1% in the general population of adults [1]. RA runs a chronic
course marked by ﬂares of synovial membrane inﬂammation
that can eventually cause joint destruction, thereby impairing
quality of life and causing disability. In addition, RA is associ-
ated with an estimated decrease in life expectancy of 10 years
Open access under [2–5]. The latest French recommendations for managing RA
were published in 2007 [6]. Since then, there have been sev-
eral major changes in concepts (e.g., treat-to-target approach,
dynamic treatment adjustment, and treatment optimization) and
 Open access under CC BY-NC-ND license.
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reatments (new data on existing treatments and introduction of
ew drugs). The publication of new recommendations is therefore
imely.
These recommendations are intended for physicians who
rovide care to RA patients, i.e., chieﬂy rheumatologists and
rimary-care physicians. They should also prove useful to health
uthorities and patient self-help organizations. They deal with
 range of issues extending from the diagnosis to the over-
ll management of RA but focus chieﬂy on the drug treatment
trategy.
. Methods
The French Society for Rheumatology (SFR) convened a task
orce composed of 8 hospital-based rheumatologists, 1 community-
ased rheumatologist, and 1 representative of a patient self-help
rganization. These 10 individuals came from various geographic
egions throughout France. Their work referred to the 2007 rec-
mmendations issued by the French National Authority for Health
HAS) and the HAS guidebook for chronic diseases (#22) [6] but
elied chieﬂy on the recently published European League Against
heumatism (EULAR) recommendations for managing RA [7]. In
articular, the task force directed careful attention to the results
f the three vast systematic literature reviews that were per-
ormed to prepare the EULAR recommendations by assessing
he efﬁcacy of synthetic disease-modifying antirheumatic drugs
DMARDs) [8], efﬁcacy of biologics [9], and safety data [10],
espectively. The task force developed the recommendations in
013, improved them by conducting several consensus-building
ounds via email, and submitted them to a review group com-
osed of 31 experts who included hospital- and community-based
heumatologists, SFR members, primary-care physicians, and a
atient self-help organization representative. The comments and
uggestions made by the review group were used to develop
he ﬁnal version of the recommendations. The level of evi-
ence and grade of each recommendation were determined
11].
. Results
Three general principles and 15 recommendations were devel-
ped (Table 1) and recapitulated in algorithm format (Fig. 1).
.1.  General principles about the management of rheumatoid
rthritis (RA)
.1.1.  The optimal management of patients with RA requires a
ialogue  between the rheumatologist and patient to ensure that
he  patient receives the information and education needed to
hare  in his or her management decisions
RA is a chronic disease and therefore requires that the patient
ontributes to his or her own management and follow-up (Table 1).
he sharing of medical decisions is the foundation of the partner-
hip between the patient and physician. To take informed decisions
egarding their own management, in partnership with the physi-
ian, the patient must receive relevant information and education.
herapeutic patient education is at the core of this recommenda-
ion: it promotes patient self-sufﬁciency and the emergence of the
atient as a fully-ﬂedged partner in the management process [6].
herapeutic patient education can be delivered during formal ses-
ions or via other means, particularly when formal sessions are not
vailable.e Spine 81 (2014) 287–297
3.1.2. The rheumatologist is the specialist who should be in
charge  of managing patients with RA. The primary-care physician
plays  a crucial role in detecting RA and in providing follow-up in
conjunction  with the rheumatologist
The  rheumatologist is the specialist who should treat and mon-
itor patients with RA. However, the primary-care physician is in
an unique position to detect potential early RA and to rapidly refer
patients with suspected RA to the rheumatologist. An early diag-
nosis followed by prompt treatment initiation is key to improving
the outcomes of RA management. Thus, the availability of effective
and fast-moving chains of care is imperative [12]. The primary-care
physician also plays an essential role in organizing and coordinating
the individualized management strategy, most notably regarding
treatment monitoring and comorbidity management. Patients with
RA are at high risk not only for disabilities related to their joint dis-
ease, but also for cardiovascular and respiratory disease, infection,
lymphoma, and osteoporotic fractures [13,14].
3.1.3. The high cost of RA, its consequences, and its treatments for
both the individual and society should be considered when
making  treatment decisions
The  treatment of RA is costly, particularly since the advent of
biologics [15,16]. However, the disease itself generates high indi-
rect costs due to loss of productivity, work incapacitation, and
surgical procedures. The treatment decisions should therefore take
into account not only the costs of treatment, but also the cost to
individuals and society of suboptimal disease management. Bio-
logics are highly effective and can therefore decrease the mid-term
and long-term costs of RA, for instance by decreasing the time spent
off work and the need for surgical procedures [17,18]. Thus, the
treatment decisions should be based chieﬂy on efﬁcacy and safety
data, while also factoring in the costs of management.
3.2. Recommendations
3.2.1. Diagnosis and organization of the management of RA
3.2.1.1.  Recommendation 1. A diagnosis of RA should be:
• considered  in patients with speciﬁc clinical ﬁndings such as joint
swelling  (clinical arthritis), morning stiffness lasting longer than
30  minutes, and a positive hand or forefoot squeeze test;
• conﬁrmed  by laboratory tests (erythrocyte sedimentation rate
[ESR],  C-reactive protein [CRP], anti-citrullinated protein anti-
bodies  [ACPA], and rheumatoid factors [RFs]) and imaging studies
(radiographs  with or without ultrasonography), after ruling out
the differential diagnoses.
Optimal patient outcomes are obtained by initiating DMARD
therapy early after symptom onset [19].
Early recognition of suspected RA by the primary-care physician
followed by prompt patient referral to a rheumatologist is therefore
crucial. Clinically, the most telling ﬁnding is synovitis, particularly
at the ﬁnger joints and wrists. A positive squeeze test provides valu-
able orientation: the pain is caused by putting pressure across the
metacarpophalangeal and/or metatarsophalangeal joints [20].
Conﬁrmation of the diagnosis of RA relies on a set of converg-
ing arguments with special attention to the absence of clinical
and laboratory data pointing to another inﬂammatory joint dis-
ease (Table 2). The most useful criteria are those developed jointly
by the American College of Rheumatology (ACR) and EULAR for
classifying RA [21] (Fig. 2). In patients with clinical synovitis in at
least one joint and no alternative diagnosis that better explains
the ﬁndings, a score ≥ 6/10 indicates RA (Fig. 2). Another impor-
tant key to the diagnosis is the presence of speciﬁc antibodies (RFs
and ACPA), which must be assayed (Table 2, Fig. 2). Imaging stud-
ies should consist of anteroposterior radiographs of the hands and
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Table  1
2014  recommendations about the management of rheumatoid arthritis issued by the French Society for Rheumatology (SFR).
General principles and recommendations Level of evidence Group agreementaMean (SD)
General principles
The  optimal management of patients with RA requires a dialogue between the rheumatologist and patient to
ensure that the patient receives the information and education needed to share in his or her management
decisions
NA 9.3 (1.2)
The rheumatologist is the specialist who  should be in charge of managing patients with RA. The primary-care
physician  plays a crucial role in detecting RA and in providing follow-up in conjunction with the rheumatologist
NA 9.6 (0.8)
The high cost of RA, its consequences, and its treatments for both the individual and society should be
considered  when making treatment decisions
NA 9.0 (1.4)
Recommendations
Diagnosis and organization of the management of RA B 9.4 (0.8)
1. A diagnosis of RA should be
Considered in patients with speciﬁc clinical ﬁndings such as joint swelling (clinical arthritis), morning stiffness
lasting  longer than 30 minutes, and a positive hand or forefoot squeeze test
Conﬁrmed by laboratory tests (erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], anti-citrullinated
protein  antibodies [ACPA], and rheumatoid factors [RFs]) and imaging studies (radiographs with or without
ultrasonography),  after ruling out the differential diagnoses
2.  As soon as RA is diagnosed, disease-modifying treatment must be initiated A 9.5 (1.0)
3. The treatment target is a remission or minimal disease activity in every patient, with the goal of preventing
structural  damage progression and the development of disabilities
A  9.4 (0.8)
4. A clinical remission is deﬁned as the absence of signs and symptoms of signiﬁcant inﬂammatory activity.
Disease  activity should be measured using validated composite criteria, including joint indices
B 9.1 (1.1)
5. Follow-up should be provided at closely spaced intervals (every 1 to 3 months) as long as the disease is
active.  Treatment adjustments are in order in patients who  fail to improve within 3 months or to achieve their
treatment target within 6 months
B 9.4 (0.8)
First-line treatment
6.  Methotrexate is the ﬁrst-line DMARD in patients with active RA; the optimal dosage should be reached
within  no more than 4–8 weeks.
A  9.4 (0.9)
7. In DMARD-naive patients who have contraindications or early intolerance to methotrexate, leﬂunomide
and  sulfasalazine are good alternatives
A  9.2 (1.0)
8. While awaiting the effects of DMARD therapy, glucocorticoid therapy can be considered, in a low
cumulative  dosage, if possible for no longer than 6 months. The glucocorticoid dose should be tapered as
promptly as possible
B 8.9 (1.6)
Second and subsequent lines of treatment
9. In patients with an inadequate response or intolerance to methotrexate and
Presence of adverse prognostic factors, add-on biologic therapy may be considered (TNF antagonist, abatacept,
tocilizumab  or, in speciﬁc situations, rituximabb)
Absence of adverse prognostic factors, combined synthetic DMARD therapy
(methotrexate/sulfasalazine/hydroxychloroquine) or a switch to another synthetic DMARD (leﬂunomide or
sulfasalazine) are good treatment options. If this strategy fails or is contraindicated, biological therapy should be
considered
D  9.0 (1.4)
10. All biologics are best used in combination with methotrexate A 9.3 (1.5)
11. Patients who fail a ﬁrst biological agent should be switched to another biological agent; patients having
failed  a ﬁrst TNF antagonist can be given either a second TNF antagonist or a biological agent with a different
mechanism  of action
A 9.0 (1.2)
Managing disease remission and global patient management
12.  In patients with a sustained remission, after discontinuation of the glucocorticoid therapy (or tapering to a
dose  ≤ 5 mg/day), a decrease in the biological agent dosage can be considered
B 9.1 (1.2)
13. In patients with a prolonged remission, a gradual decrease in the synthetic DMARDs can be considered, as
a medical decision shared by the patient and physician
C 8.6 (1.5)
14. Treatment selection and adjustment should factor in a number of considerations in addition to measured
disease  activity, such as structural disease progression, comorbidities, tolerance of the drugs, and the patient’s
wishes
C  9.6 (0.7)
15. Patients with RA should be offered a global management program including not only drug treatments, but
also therapeutic education, comorbidity management and, as appropriate, psychological support, assistance
with  social and occupational issues, functional rehabilitation, and/or surgery
C 9.4 (1.0)
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a Agreement was  scored from 0 to 10 with 10 indicating unanimity.
b In particular, in the event of contraindications to other biologics.
rists, anteroposterior and oblique radiographs of the forefeet, and
 chest radiograph [6]. Patients who fail to meet the clinical and
aboratory ACR/EULAR criteria but who have radiographic erosions
ypical for RA can also be classiﬁed as having RA (Fig. 2). The EULAR
ecently deﬁned typical RA erosions as the presence of erosions in
t least three joints among the metacarpophalangeal joints, proxi-
al  interphalangeal joints, wrists, and metatarsophalangeal joints
22]. Finally, Doppler ultrasonography can be useful to conﬁrm the
resence of synovitis, monitor disease activity and progression, and
valuate persistent inﬂammation [23].
.2.1.2. As soon as RA is diagnosed, disease-modifying treatment must
e initiated (recommendation 2). RA is a therapeutic emergency:eing the highest possible grade. NA: not applicable.
early,  specialized, personalized, multidisciplinary management
must be provided immediately. The promptness with which treat-
ment is initiated largely governs the patient outcomes. Abundant
published data support the existence of this window of opportunity
for effectively treating RA [19,24–26]. Rapid initiation of effective
treatment may  increase the chances of achieving a remission, limit
the functional impairments, and decrease the degree of structural
damage [12,27–29].3.2.1.3.  The treatment target is a remission or minimal disease activ-
ity in every patient, with the goal of preventing structural damage
progression and the development of disabilities (recommendation
3). Achieving a remission or minimal disease activity improves
290 C. Gaujoux-Viala et al. / Joint Bone Spine 81 (2014) 287–297
Fig. 1. Algorithm for the management of rheumatoid arthritis based on the 2014 recommendations issued by the French Society for Rheumatology (SFR).
C. Gaujoux-Viala et al. / Joint Bon
Table  2
Routine laboratory tests required in patients with recent-onset polyarthritis [6].
Erythrocyte sedimentation rate and C-reactive protein
Blood  cell counts
Transaminases
Serum  creatinine; urinary dipstick (proteinuria, hematuria)
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[Rheumatoid factors and anti-citrullinated peptide antibodies (ACPA)
Antinuclear antibodies (ANA)
Viral serological tests: hepatitis B and C (as part of the pretreatment workup)
id-term and long-term structural and functional outcomes [30]
nd may  diminish the excess mortality, particularly due to cardio-
ascular disease [31].
Achieving  a remission should be the main treatment objective
n every patient, particularly in early-onset RA. The chances of
chieving a remission are lower in patients with advanced RA
nd/or marked structural damage, and achieving minimal disease
ctivity is an acceptable alternative in this situation [7].
.2.1.4.  A clinical remission is deﬁned as the absence of signs and
ymptoms of signiﬁcant inﬂammatory activity. Disease activity should
e measured using validated composite criteria, including joint indices
recommendation 4). A clinical remission can be deﬁned as the
bsence of clinical signs and symptoms of inﬂammation. In practice,
atients should be evaluated using composite activity indices such
s the Disease Activity Score 28 (DAS28), with values no greater
han 2.6 indicating a remission and values no greater than 3.2 min-
mal disease activity [32]. Other composite indices that include
oint counts can be used such as the Simpliﬁed Disease Activity
ndex (SDAI), with scores no greater than 3.3 indicating a remission
nd scores in the 3.3–11 range indicating minimal disease activity
33]; or the Clinical Disease Activity Index (CDAI), for which the
orresponding score values are ≤ 2.8 and 2.8–10 [34]. It is worth
oting that the DAS28 is the least restrictive in deﬁning a remis-
ion [35] and that the DAS28-CRP, which is less restrictive than
he DAS28-ESR, has no validated cutoffs for remission or minimal
isease activity [36,37]. The new ACR/EULAR deﬁnition of RA remis-
ion issued in 2011 requires values ≤ 1 for the tender and swollen
oint counts, CRP level (mg/dL), and global evaluation by the patient
0–10 visual analog scale [VAS]) [38]. However, even in the absence
f objective evidence of inﬂammation, a non-negligible proportion
f patients have a global VAS score > 1/10 [39]. Thus, the ACR/EULAR
eﬁnition of disease remission may  be excessively restrictive for
veryday practice. In situations that are challenging to evaluate
e.g., ﬁbromyalgia or pain due to sequelae), particular importance
ig. 2. Classiﬁcation criteria for rheumatoid arthritis developed by the American
ollege  of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
21].e Spine 81 (2014) 287–297 291
should be given to joint swelling and laboratory evidence of sys-
temic inﬂammation. Other items not considered in these indices
may be helpful such as morning stiffness duration, nocturnal awak-
enings, pain intensity, and extra-articular manifestations.
3.2.1.5. Follow-up should be provided at closely spaced intervals
(every 1 to 3 months) as long as the disease is active. Treatment
adjustments are in order in patients who fail to improve within 3
months or to achieve their treatment target within 6 months (recom-
mendation 5). Closely spaced follow-up evaluations and frequent
treatment adjustments (every 1 to 3 months) are required as
long as the treatment target has not been achieved. This con-
cept of tight disease control with a dynamic treatment strategy
[40] and a clearly deﬁned objective constitutes the treat-to-target
approach [41]. Tight disease control involves matching the treat-
ment to the activity of the disease. The usefulness of this strategy
has been conﬁrmed in numerous studies including meta-analyses
[42]. Tight disease control improves the quality of disease control,
decreases the need for surgical procedures, and decreases the risk
of death and cardiovascular events such as myocardial infarction
[43–45].
In patients who are not improved after 3 months (e.g., who do
not have an at least 1.2-point improvement in the DAS28 or a tran-
sition from high to moderate disease activity) and those who have
not achieved their treatment target (remission or minimal disease
activity) after 6 months, the treatment strategy should be reap-
praised and, in most cases, the disease-modifying treatment should
be adjusted or changed.
The  functional impact of the disease should be evaluated once a
year (e.g., using the Health Assessment Questionnaire). This eval-
uation not only provides a snapshot of the current status of the
patient, but also predicts future outcomes (in terms of clinical man-
ifestations, structural damage, work ability, and risk of death) [17].
Structural disease progression should be evaluated on radiographs
of the hands and feet obtained every 6–12 months the ﬁrst year
then once a year for 3–5 years, and subsequently at wider intervals
and whenever the treatment is changed.
3.2.2. First-line treatment
3.2.2.1.  Methotrexate is the ﬁrst-line DMARD in patients with active
RA; the optimal dosage should be reached within no more than
4–8 weeks (recommendation 6). Methotrexate is the recommended
ﬁrst-line DMARD in RA based on its effectiveness, fairly good
safety proﬁle, and moderate cost [7,46–50]. The recommended
starting dosage is 10–15 mg/week orally followed by rapid dose
escalation (e.g., 5-mg increments every 1–4 weeks) to achieve the
optimal dosage of about 0.3 mg/Kg/week, i.e., 15–25 mg/week in
most patients, depending on effectiveness and safety, as well as
on the speciﬁc characteristics of each patient. In the event of an
inadequate treatment response or failure to tolerate methotrexate,
subcutaneous administration of the drug can be considered. Finally,
supplementation with at least 5 mg/week of folic acid at a distance
from the methotrexate dose is recommended [51].
Methotrexate is thus the ﬁrst-line drug in patients with active
RA. A major issue is whether methotrexate should be used
alone or combined with other synthetic DMARDs. A Cochrane
Collaboration meta-analysis published in 2010 found no improve-
ment in the risk/beneﬁt ratio with drug combinations compared
to methotrexate alone [52]. Two  recent studies compared the
clinical and structural efﬁcacy of the triple drug combination
methotrexate + sulfasalazine + hydroxychloroquine to methotrex-
ate alone [53,54]. One of these studies, tREACH, was a randomized
controlled single-blind trial in patients with recent-onset RA at
high risk for progression to established RA but without speciﬁc
criteria of adverse prognostic signiﬁcance [53]. Glucocorticoid ther-
apy was given also. Some of the study parameters showed greater
2 t Bon
i
T
a
e
a
p
t
b
b
a
a
a
m
o
3
i
a
o
b
t
t
a
t
2
g
y
D
d
s
3
t
n
p
p
H
c
c
s
i
A
I
1
(
c
r
[
c
r
c
o
t
d
T
p
u
5
m
R
c
n
certolizumab-pegol, etanercept, and golimumab; and inﬂiximab,
given as intravenous infusions), the interleukin 6-receptor antago-
nist tocilizumab, et the T-cell co-stimulation modulator abatacept.92 C. Gaujoux-Viala et al. / Join
mprovements with the triple drug combination. The other study,
EAR, involved tight disease control with dynamic treatment
djustments to achieve a predeﬁned target and found no differ-
nces in clinical or radiographic outcomes between triple therapy
nd methotrexate alone [54]. The CareRA study done in Belgium
rovided new information in late 2013 [55]. This randomized con-
rolled trial found no evidence that triple DMARD therapy was
etter than methotrexate alone (with glucocorticoid therapy in
oth treatment arms) [55]. Finally, patient acceptance of triple ther-
py is sometimes poor (e.g., due to the large number of tablets and
dverse events), a fact that translates into low treatment continu-
tion rates [56].
Thus,  given the inadequate amount of consistent data,
ethotrexate alone is recommended for the ﬁrst-line treatment
f active RA.
.2.2.2.  In DMARD-naive patients who have contraindications or early
ntolerance to methotrexate, leﬂunomide and sulfasalazine are good
lternatives (recommendation 7). In patients with contraindications
r intolerance to methotrexate, leﬂunomide and sulfasalazine have
een proven effective in alleviating the symptoms and decreasing
he structural damage [57]. A meta-analysis of randomized con-
rolled trials showed similar efﬁcacy of leﬂunomide or sulfasalazine
nd methotrexate, although the methotrexate dosages were subop-
imal [57]. The usual dosage is 3 g/day for sulfasalazine [58,59] and
0 mg/day for leﬂunomide. The absence of contraindications and
ood tolerance of these treatments should be checked. Hydrox-
chloroquine can be useful in combination with other synthetic
MARDs or with biologics but is not recommended alone in RA
ue to its weak and delayed clinical efﬁcacy and absence of proven
tructural effects [57].
.2.2.3.  While awaiting the effects of DMARD therapy, glucocorticoid
herapy can be considered, in a low cumulative dosage, if possible for
o longer than 6 months. The glucocorticoid dose should be tapered as
romptly as possible (recommendation 8). Nearly one of every three
atients with RA receives long-term glucocorticoid therapy [60].
owever, the risk/beneﬁt ratio of glucocorticoid therapy remains
ontroversial.
In addition to symptomatic effects, structural effects of glu-
ocorticoids were documented in several studies [61–65]. The
tructural efﬁcacy of glucocorticoid therapy has been proven only
n recent-onset RA and over a treatment duration of 1–2 years [65].
 recently reported 2-year randomized controlled trial (CAMERA
I) compared methotrexate alone to methotrexate plus prednisone
0 mg/day [66]. After 2 years, the modiﬁed Sharp erosion score
primary outcome measure) was signiﬁcantly lower in the gluco-
orticoid group, which also had signiﬁcantly fewer patients free of
adiographic disease progression (78% versus 67% with the placebo)
66]. However, the use of a 10-mg prednisone dose for 2 years raises
oncerns, particularly regarding safety.
In a meta-analysis, the rate of adverse events in RA patients
eceiving glucocorticoid therapy was 43/100 patient-years (95%
onﬁdence interval, 30–55) [67]. A case-control study in RA patients
lder than 65 years of age showed an increased risk of severe infec-
ion that was proportional not only to the current glucocorticoid
osage but also to the cumulative dosage over 2–3 years [68].
he excess risk of severe infection occurred even with low-dose
rednisone therapy (5 mg/day). In addition, two recent studies doc-
mented an increase in mortality among patients taking more than
 mg/day of glucocorticoids [31,69].
The task force took into account these data on the efﬁcacy andid-term safety of glucocorticoid therapy combined with DMARDs.
ecommendation #8 supports low-dose prednisone therapy, in
ombination with a DMARD, in patients with active RA, most
otably early in the course of the disease; but also advisese Spine 81 (2014) 287–297
restrictions regarding the dosage and duration of prednisone ther-
apy. A daily dosage of 0.15 mg/Kg can be suggested as a guide but
should be tapered as promptly as possible. The maximum treat-
ment duration of 6 months, although not substantiated by strong
evidence, nevertheless generated a consensus among the task force
members given the data in the literature. Although the cumulative
dose is important to consider in individual patients, a strict rec-
ommendation applicable to the majority of patients is difﬁcult to
develop. An alternative to daily oral glucocorticoid therapy is par-
enteral methylprednisolone therapy, 80 to 120 mg,  which has the
advantage of avoiding weaning difﬁculties [53].
In every case, as with all treatments, glucocorticoid therapy
requires a careful risk/beneﬁt assessment in each individual patient
and routine measures to prevent adverse effects, most notably
glucocorticoid-induced osteoporosis [70].
Intra-articular glucocorticoid injections are often used as an
alternative or adjunct to systemic glucocorticoid therapy. They can
alleviate the local symptoms and inﬂammation and induce few side
effects [71].
3.2.3.  Second and subsequent lines of treatment
3.2.3.1. Inadequate response or intolerance to methotrexate (rec-
ommendation 9). In patients with an inadequate response or
intolerance to methotrexate and:
• presence of adverse prognostic factors, add-on biologic therapy
may  be considered (TNF antagonist, abatacept, tocilizumab or,
in  speciﬁc situations, rituximab2);
• absence  of adverse prognostic factors, combined synthetic
DMARD therapy (methotrexate/sulfasalazine/hydroxychloro-
quine)  or a switch to another synthetic DMARD (leﬂunomide or
sulfasalazine) are good treatment options. If this strategy fails or
is contraindicated, biological therapy should be considered.
This recommendation differentiates two strategies based on the
prognostic factors. Outcome prediction relies in particular on the
combination of the following criteria: presence or progression of
structural damage (the main criterion), marked clinical and/or lab-
oratory activity, and high titers of rheumatoid factors and/or ACPA
[72–75].
In patients with an inadequate response or intolerance to
methotrexate but no factors of adverse prognostic signiﬁcance,
the recommended treatment is either combined synthetic DMARD
therapy (e.g., methotrexate + sulfasalazine + hydroxychloroquine)
or substitution of another synthetic DMARD for the methotrexate.
The role for combination synthetic DMARD therapy was recently
a focus of controversy, as discussed in part in recommendation #6
(Section 3.2.2.1). The task force considered that the triple drug com-
bination should not be used for the ﬁrst-line treatment of RA but is
supported by recent data for the second-line treatment of patients
who have no factors of adverse prognostic signiﬁcance. A suggested
alternative consists in switching to another synthetic DMARD used
alone [76].
In  patients with factors of adverse prognostic signiﬁcance
(structural damage, marked clinical and/or laboratory activity, high
RF and/or ACPA titers), add-on biological therapy can be consid-
ered. The biologics licensed for use in this indication are TNF
antagonists (four given subcutaneously, namely, adalimumab,All these biological agents have been proven effective in alleviat-
2 In particular, in the event of contraindications to other biologics.
t Bon
i
p
w
o
m
p
g
c
t
t
R
s
I
g
5
t
h
3
a
a
o
o
[
i
D
a
r
a
p
b
a
p
t
t
g
t
[
c
t
[
a
c
3
a
c
a
ﬁ
i
T
s
v
d
c
a
w
c
s
o
mC. Gaujoux-Viala et al. / Join
ng the symptoms and slowing structural disease progression in
atients with RA refractory to methotrexate [9,77]. The task force
as unable to identify one of these biologics as preferable over the
thers, since the efﬁcacy and safety proﬁles were similar in several
eta-analyses and a few head-to-head trials; and since no factors
redicting the response to a given biologic are available to date for
uiding drug selection [78–80]. It is worth noting, however, that
urrent practice favors the initial use of a TNF antagonist, given
he 15 years of clinical experience and excellent structural efﬁcacy
hat characterize this drug class.
Rituximab is not licensed for use as a ﬁrst-line biological agent in
A. However, rituximab therapy can be considered in uncommon
ituations that generate difﬁculties in using other biological agents.
n particular, the task force pointed out that rituximab may  be a
ood choice in patients with a history of cancer within the past
 years, a history of lymphoma, latent tuberculosis with an obstacle
o effective chemoprophylaxis, a high risk of tuberculosis, and a
istory of multiple sclerosis.
.2.3.2.  All biologics are best used in combination with methotrex-
te (recommendation 10). There is no published evidence that
 TNF antagonist, rituximab, or abatacept alone is superior
ver methotrexate alone. In contrast, adding at least 10 mg/week
f methotrexate increases the efﬁcacy of biologic therapy
81,82].
In addition, combining methotrexate with a biologic agent
mproves the biologic treatment continuation rate in RA. In the
utch DREAM registry, for instance, the 1337 patients given a TNF
ntagonist combined with methotrexate had better continuation
ates compared to the 355 patients given a TNF antagonist and
nother synthetic DMARD, and continuation was lowest in the 261
atients given a TNF antagonist alone [83].
Tocilizumab is in a unique position, as several studies found
etter outcomes with tocilizumab alone than with methotrexate
lone [84–87]. In the ACT-RAY randomized controlled trial in 556
atients with RA refractory to methotrexate therapy alone, add-on
ocilizumab was compared to switching to tocilizumab. Whereas
he 6-month data suggested similar efﬁcacy with these two  strate-
ies, after 1 year a trend was found toward better outcomes with
ocilizumab plus methotrexate compared to methotrexate alone
88].
Thus, regardless of the biologic chosen, a synthetic DMARD,
hieﬂy methotrexate, should be given concomitantly. Other syn-
hetic DMARD options are leﬂunomide and even sulfasalazine
89,90]. However, should a biological agent have to be used
lone, there is evidence that tocilizumab may  constitute the best
hoice.
.2.3.3. Patients who fail a ﬁrst biological agent should be switched to
nother biological agent; patients having failed a ﬁrst TNF  ˛ antagonist
an be given either a second TNF  ˛ antagonist or a biological agent with
 different mechanism of action (recommendation 11). Failure of a
rst biological agent warrants a switch to another biological agent
f warranted by the activity of the disease.
After failing a TNF antagonist, patients may  be given another
NF antagonist, abatacept, rituximab, or tocilizumab. In this
ituation, there is no clear evidence that one biological agent pro-
ides better efﬁcacy than the others [91] and the choice therefore
epends chieﬂy on the medical history of the patient and the
haracteristics of the drug (route of administration, half-life, and
dverse events). For instance, rituximab may  be useful in patients
ith a recent history of cancer or recent treatment for active tuber-
ulosis. The preliminary data from the French ROC trial of treatment
trategies in patients with an inadequate response to TNF antag-
nist therapy suggest that a biological agent having a different
echanism of action (abatacept, rituximab, or tocilizumab) maye Spine 81 (2014) 287–297 293
provide greater efﬁcacy than a second TNF antagonist [92]. How-
ever, this ﬁnding was  not conﬁrmed in a Dutch study comparing a
second TNF antagonist to abatacept or rituximab [83]. It may  be
of interest to distinguish primary failure (no response to the TNF
antagonist) and secondary escape phenomenon (initial response
that wanes over time). The probability of a response to a second
TNF antagonist may  be greater when the ﬁrst TNF antagonist
was stopped because of escape phenomenon as opposed to pri-
mary failure [93,94]. The task force considered that studies of TNF
antagonist therapy monitoring (serum drug assays and assays of
antibodies to biologics) should be continued to try to assist clini-
cians in selecting the best second-line biologic after failure of TNF
antagonist therapy [95].
3.2.4.  Managing disease remission and global patient
management
3.2.4.1. In patients with a sustained remission, after discontinuation
of the glucocorticoid therapy (or tapering to a dose ≤ 5 mg/day), a
decrease in the biological agent dosage can be considered (recommen-
dation 12). The deﬁnition of a sustained remission is not universally
agreed on but is usually considered as involving the persistence of
the remission for at least 6 months. Studies of patients with long-
standing RA showed that relapses were common after abrupt TNF
antagonist therapy discontinuation [96–98] and that a stronger
and more lasting therapeutic response before discontinuation pre-
dicted a greater probability of a sustained response with synthetic
DMARD therapy alone [96]. Biological agent dosage de-escalation
may be a better strategy than sudden discontinuation [99]. The
French STRASS study is a randomized controlled double-blind trial
comparing a gradual increase in the TNF antagonist dosing inter-
val to keeping the interval unchanged in patients on etanercept or
adalimumab combined with a glucocorticoid ≤ 5 mg/day after at
least 6 months of DAS28 remission [100]. After 18 months, increas-
ing the TNF antagonist dosing interval had proven feasible in
three-fourths of patients and TNF antagonist discontinuation in
37.5% [100]. In recent-onset RA, although the treatment goal is
clearly to achieve a remission, some de-escalation studies focused
on patients with minimal disease activity. Despite differences in the
methodologies and results, the data indicate that de-escalation (via
dosage reduction or wider dosing intervals) is often feasible but that
abrupt discontinuation is frequently followed by a relapse and that
a remission without treatment is rarely achieved [101–103]. The
data on de-escalation of biologics other than TNF antagonists are
scarce but suggest similar conclusions [104–106]. Interestingly, the
reintroduction of biological therapy in the event of a relapse may
allow the return to a favorable outcome [96,104,107].
In some patients, a clinical remission may coincide with con-
tinued structural disease progression [108–110]. Consequently,
radiographs should be obtained before and throughout de-
escalation to check that the clinical remission is accompanied with
a halt in radiographic lesion progression.
Importantly, before considering de-escalation via a dosage
reduction or increased dosing intervals, the glucocorticoid ther-
apy should ﬁrst be stopped or brought down to the minimal dose
(≤ 5 mg/day) if complete discontinuation proves impossible.
3.2.4.2. In patients with a prolonged remission, a gradual decrease in
the synthetic DMARDs can be considered, as a medical decision shared
by the patient and physician (recommendation 13). Currently avail-
able data suggest that methotrexate dosage reduction may  deserve
consideration in patients in remission for at least 6 months under
methotrexate therapy [111,112]. Again, dosage reduction seems
preferable over the abrupt discontinuation of methotrexate or any
other synthetic DMARD. Abrupt discontinuation is associated with
a high relapse rate of about 70%, i.e., 2-fold that seen with contin-
ued treatment [113–115], and the reintroduction of the synthetic
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MARD only inconsistently restores the previous status [116]. It
ould seem important to deﬁne a sustained remission using a strict
omposite criterion including the absence of synovitis, systemic
nﬂammation, and structural disease progression [38,108–110].
.2.4.3.  Treatment selection and adjustment should factor in a num-
er of considerations in addition to measured disease activity, such as
tructural disease progression, comorbidities, tolerance of the drugs,
nd the patient’s wishes (recommendation 14). Before making treat-
ent decisions, the results of disease activity indices should be
nterpreted based not only on an analysis of the individual index
omponents, but also on the patient’s characteristics, most notably
he comorbidity proﬁle. It should be borne in mind, however, that
igh RA activity is often associated with a heavier comorbidity
urden [117,118] and that effective RA treatment may prevent cer-
ain comorbidities [119,120]. Other important considerations are
he tolerance of the drugs by the patient and the patient’s wishes,
hich are strongly relevant to shared decision-making and good
reatment adherence. Finally, some patients have low disease activ-
ty yet continue to experience structural disease progression, as
iscussed in recommendation 12 (Section 3.2.4.1).
.2.4.4. Patients with RA should be offered a global management
rogram including not only drug treatments, but also therapeutic edu-
ation, comorbidity management and, as appropriate, psychological
upport, assistance with social and occupational issues, functional
ehabilitation, and/or surgery (recommendation 15). The manage-
ent approach should be global: pharmacotherapy, physical
herapy, psychotherapy and, if needed, surgery act complementar-
ly and are inseparable from appropriate assistance with social and
ccupational issues. Non-pharmacological interventions should
e considered and may  include [6] physical treatments (physio-
herapy, occupational therapy, and pedicures or podiatric care);
ehabilitation and changes to the environment; therapeutic patient
ducation, psychological support, and dietary therapy.
In  addition, the high prevalence of cardiovascular morbid-
ty in RA patients mandates routine and regular evaluations of
ther cardiovascular risk factors, which should be corrected when-
ver possible (smoking cessation and treatments for dyslipidemia,
ypertension, diabetes, and obesity). Given the reported associ-
tions between RA and periodontal disease, attention to dental
ygiene is recommended [121,122]. Referral for advice from a sur-
eon may  be order, most notably in patients at risk for tendinopathy
nd in those with severe joint destruction.
Finally, patients with RA should be informed about the existence
f self-help organizations, particularly at the time of diagnosis, and
ontact information should be supplied if agrees by the patient.
.  Discussion
The management of RA has beneﬁted over the last 15 years from
ajor breakthroughs in the ﬁeld of drug therapy, including opti-
ization of synthetic DMARD therapy, commercial availability of
iological DMARDs, low-dose glucocorticoid therapy, and combi-
ations of drugs belonging to different classes. No less important
re the conceptual advances achieved in recent years, which under-
ine the pivotal role for the rheumatologist as the physician of
eference for the management of RA, the importance of shared
ecision-making in which the patient is viewed as a partner, the
dentiﬁcation of a therapeutic window, and the desirability of tight
isease control.
The  SFR recommendations are recapitulated in a simple and
asy-to-use algorithm for managing RA (Fig. 1). They are intended
or all physicians involved in caring for patients with RA. These
ew SFR recommendations are consistent with existing recom-
endations [6] and incorporate recently published data [8–10].e Spine 81 (2014) 287–297
Nevertheless,  they encompass a vaster ﬁeld than do the Euro-
pean recommendations, since they extend from the diagnosis to
global patient management, despite a strong emphasis on treat-
ment. Importantly, the high level of evidence underlying most of
the recommendations results in strong adhesion and high recom-
mendation grades. Nevertheless, a few items rely on expert opinion
or on a combination of scientiﬁc evidence and expert opinion,
indicating a need for a vast array of research projects designed
to resolve these points. A number of situations encountered in
RA patients continue to raise challenges and warrant continued
work to develop new treatments. Several drugs are being devel-
oped (e.g., JAK inhibitors, IL-6 antagonists, and biosimilars). Thus,
the present recommendations reﬂect currently available scientiﬁc
evidence and will need to be updated regularly.
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